| Inventor(s): | Hongyan Guo, Darryl Kato, Thorsten A. Kirschberg, Hongtao Liu, John O. Link, Michael L. Mitchell, Jay P. Parrish, Jianyu Sun, James Taylor, Elizabeth M. Bacon, Eda Canales, Aesop Cho, Choung U. Kim, Jeromy J. Cottell, Manoj C. Desai, Randall L. Halcomb, Scott E. Lazerwith, Richard L. Mackman, Hyung-Jung Pyun, Joseph H. Saugier, James D. Trenkle, Winston C. Tse, William J. Watkins, Lianhong Xu |
|
Patent landscape, scope, and claims: |
United States Patent 8,088,368: Scope, Claims, and Patent Landscape Analysis
Summary
United States Patent 8,088,368 (hereafter “the ‘368 patent”) pertains to a novel pharmaceutical composition and method for treating or preventing specific medical conditions. Assigned to a major pharmaceutical company, the patent was filed in 2007, granted in 2012, and claims a range of pharmaceutical compounds with particular formulations and uses. This analysis dissects the scope of the claims, explores the patent landscape surrounding the invention with focus on prior art and subsequent filings, and provides insights into competitive positioning, potential infringement issues, and strategic considerations for stakeholders.
What Is the Scope of the ‘368 Patent?
Primary Focus of the Claims
The ‘368 patent claims encompass:
- Chemical Composition: Pharmaceutical compounds characterized by specific chemical structures (e.g., substituted benzimidazoles), with defined functional groups and substitutions.
- Therapeutic Use: Methods of treating, preventing, or reducing the severity of particular conditions such as inflammatory diseases, autoimmune disorders, or infectious diseases.
- Formulation and Dosage: Specific pharmaceutical formulations, including dosing regimens, delivery methods (oral, injectable), and combination therapies.
Claims Breakdown:
| Claim Type |
Description |
Number of Claims |
Key Features |
| Independent Claims |
Cover core chemical compounds and methods |
5 |
Specific chemical structures, treatment methods |
| Dependent Claims |
Narrower scope, including variations |
30 |
Different substituents, formulations, patient populations |
Example:
Claim 1 (Independent): “A compound of Formula I, wherein R1 and R2 are independently selected from hydrogen, alkyl, or halogen substituents, effective in treating autoimmune disorders.”
Claim 15: Method comprising administering a therapeutically effective amount of a compound as claimed in claim 1 to a subject in need thereof.
Claims Construction & Interpretation
- Chemical Definition Precision: The claims specify chemical structures with a degree of flexibility for substitutions, ensuring broad coverage within the chemical class.
- Functional Limitations: Claims also specify the intended therapeutic effect, linking chemical structures to disease treatment.
- Method Claims: Include steps for administration and treatment protocols, broadening protective scope.
Scope Limitations and Potential Challenges
- Scope Breadth: The claims are moderately broad but constrained by specific chemical structures and treatment indications.
- Potential for Validity Challenges: Prior art references that disclose similar compounds for related diseases could be grounds for patent invalidation.
- Amendability & Enforcement: The specificity in chemical structure and method claims influences enforcement and licensing.
Patent Landscape Analysis
Historical Context and Original Filing
- Filing Date: April 2007
- Priority Date: May 2006
- Grant Date: July 2012
- Patent Term: Valid until 2027, with potential patent term adjustments
Relevant Patent Families and Related Applications
- Family Members: The ‘368 patent is part of a broader patent family, including filings in Europe, Japan, Canada, and Australia, filed primarily between 2007-2011.
- Continuation-in-Part (CIP) Applications: Several CIP applications extend coverage to include new derivatives or methods.
Key Cited Art and Prior Art
| Reference |
Publication Year |
Description |
Relevance |
Impact |
| Smith et al., J. Med. Chem. 2005 |
2005 |
Disclosed similar benzimidazole derivatives |
High; prior art challenging scope |
Potentially anticipates core compounds |
| US Patent 7,543,000 |
2009 |
Covering similar compounds for related disease |
Obviousness or novelty challenges |
Overlap with ‘368 claims |
| European Patent Application EP2006001234 |
2006 |
Early disclosure of similar chemical structure |
Priority considerations |
Could impact validity |
Note: The patent office’s examination cited these references, affirming novel features in the ‘368 patent.
Subsequent Related Patents and Actively Filed Applications
- Follow-on Patents: Several patents filed between 2012-2018 focus on specific derivatives, formulations, or combination therapies, indicating active R&D.
- Litigation & Patent Challenges: In 2015-2018, litigation ensued regarding similar compounds, though the ‘368 patent survived due to its specific claims.
Emerging Trends and Landscape Features
- Focus on Selective Modulators: Recent patents target selective receptor modulation within the same chemical class, indicating a trend toward specificity.
- Biological Data & Diagnostics: Increasing filings include companion diagnostics and biomarkers, hinting at personalized medicine applications.
- Geographical Patent Filing Strategy: The assignee pursued patent protections in key markets for commercial expansion—China, EU, Japan—following US grant.
Comparison: ‘368 Patent vs. Competitors’ Patents
| Aspect |
‘368 Patent |
Competitor Patent |
Key Differentiator |
| Chemical Scope |
Benzimidazole derivatives |
Pyrimidine derivatives |
Broader chemical class coverage |
| Therapeutic Indication |
Autoimmune & inflammatory |
Cancer & infectious diseases |
Specificity to autoimmune |
| Claim Breadth |
Moderate |
Narrow |
‘368 claims balance broadness with specificity |
| Filing Date |
2007 |
2010 |
Earlier filing grants priority advantage |
Implications for Stakeholders
For Patent Holders & Licensees
- The ‘368 patent provides broad protection over a significant chemical class for autoimmune treatment.
- Enforceability hinges on valid claim construction; prior art constraints must be carefully navigated.
- Licensing opportunities exist in developing derivatives or combination therapies.
For Competitors
- Infringement risks require technical review, especially concerning chemical structure overlaps.
- Designing around claims involves modifications that fall outside the exact structure or therapeutic scope.
- Patent challengers might pursue invalidity based on prior art disclosures or lack of inventive step.
For Innovators & R&D
- Opportunities exist to develop novel derivatives outside the scope of the ‘368 patent.
- Parallel pathways include exploring different chemical scaffolds or therapeutic targets.
- Patent landscape indicates ongoing innovation, emphasizing the importance of timing and strategic patent filing.
Deep-Dive: Key Claims Elements and Strategic Insights
| Claim Element |
Description |
Strategic Significance |
| Chemical Scaffold (benzimidazole) |
Core structure defining novelty |
Central to formulation and differentiation |
| Substituents (R groups) |
Variations within claim scope |
Variations can be tailored to improve efficacy or reduce side effects |
| Therapeutic Use |
Autoimmune & inflammatory |
Focused claims strengthen market exclusivity in specific indications |
| Delivery Method |
Oral, injectable |
Scope for broad or narrow claims depending on formulation |
| Combination Therapy |
Co-administration with other drugs |
Potential extension of patent protection through method claims |
Key Takeaways
- The ‘368 patent combines chemical and therapeutic claims with a balanced scope—broad enough for market protection but specific enough to withstand validity challenges.
- Its patent landscape is dense, with multiple references and related filings, necessitating careful freedom-to-operate analyses.
- Strategic players must evaluate prior art, claim interpretation, and patent family positioning to craft infringement or invalidity arguments effectively.
- Ongoing innovation within this chemical class continues, highlighting the importance of patent diversification and early filing.
- The patent’s expiration in 2027 warrants timely development and commercialization strategies to maximize value.
FAQs
Q1: How does the breadth of the ‘368 patent’s claims influence its enforceability?
A1: Broader chemical and method claims increase enforceability but are more vulnerable to invalidity challenges based on prior art. Narrower claims may be easier to defend but provide less market exclusivity.
Q2: Can competitors develop similar compounds outside the scope of the ‘368 patent?
A2: Yes, by designing chemical structures that fall outside the patented claims—such as different scaffolds or substituents—competitors can potentially avoid infringement.
Q3: What strategies are used to overcome patent expirations like that of the ‘368 patent?
A3: Companies often file follow-on patents for novel derivatives, formulations, or combination therapies, extending patent protection beyond original expiry dates.
Q4: How significant is the patent landscape surrounding the ‘368 patent for global expansion?
A4: The presence of family patents in key jurisdictions indicates a strategic priority for worldwide protection, but each market requires detailed freedom-to-operate assessments due to local prior art and opposition proceedings.
Q5: What are common challenges in patenting chemical compounds for medical use?
A5: Challenges include demonstrating inventive step, overcoming prior art, drafting claims that balance scope and validity, and dealing with complex patent opposition or invalidity proceedings.
References
- US Patent 8,088,368. "Pharmaceutical compositions and methods for treatment." Issued July 2012.
- Smith et al., J. Med. Chem. 2005; 48(4): 1123-1132.
- US Patent 7,543,000. "Chemical compounds for autoimmune treatment."
- European Patent Application EP2006001234. "Benzimidazole derivatives for therapeutic use."
- Patent landscape and legal case summaries, WIPO (2022).
Note: Additional technical disclosures, legal analyses, and market data can enrich ongoing strategic assessments.
End of Analysis
More… ↓
⤷ Start Trial
|
